Avidity Biosciences Newsroom

Avidity Biosciences Analyst Ratings

BenzingaJun 12 13:52 ET

Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $45

BenzingaJun 12 13:52 ET

Avidity Biosciences Analyst Ratings

BenzingaJun 10 07:00 ET

Avidity Biosciences Analyst Ratings

BenzingaMay 10 07:01 ET

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA) and Curaleaf Holdings (OtherCURLF)

TipRanksMay 10 05:36 ET

Buy Rating Justified for Avidity Biosciences Amid Strong Drug Candidate Prospects and Regulatory Advancements

TipRanksMay 9 05:20 ET

Avidity Biosciences Analyst Ratings

BenzingaMay 3 06:21 ET

Avidity Biosciences Analyst Ratings

BenzingaApr 11 07:24 ET

Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)

TipRanksApr 11 06:45 ET

Avidity Biosciences Analyst Ratings

BenzingaMar 14 07:38 ET

Avidity Biosciences: Strong Buy Rating Amidst Positive Clinical Developments and Price Target Surge

TipRanksMar 6 23:31 ET

Optimistic Buy Rating for Avidity Biosciences Backed by Promising Phase 3 Study Design and Positive MARINA OLE Data

TipRanksMar 5 05:05 ET

Analysts' Top Healthcare Picks: Avidity Biosciences (RNA), Irhythm Technologies (IRTC)

TipRanksMar 5 05:05 ET

Buy Rating Affirmed for Avidity Biosciences Following Promising MARINA-OLE Study Data and RNA Analysis

TipRanksMar 4 21:45 ET

Avidity Biosciences Analyst Ratings

BenzingaMar 4 13:11 ET

Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target

BenzingaMar 4 13:10 ET

Analysts Are Bullish on These Healthcare Stocks: Avidity Biosciences (RNA), Revance Therapeutics (RVNC)

TipRanksFeb 29 07:11 ET

TD Cowen Reaffirms Their Buy Rating on Avidity Biosciences (RNA)

TipRanksFeb 28 22:05 ET

Buy Rating on Avidity Biosciences Amid Promising Clinical Milestones

TipRanksJan 10 05:41 ET

Wells Fargo Reiterates Overweight on Avidity Biosciences, Maintains $50 Price Target

BenzingaJan 3 13:11 ET